» Articles » PMID: 24498068

Mitogen-induced B-cell Proliferation Activates Chk2-dependent G1/S Cell Cycle Arrest

Overview
Journal PLoS One
Date 2014 Feb 6
PMID 24498068
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

B-cell activation and proliferation can be induced by a variety of extracellular stimuli. The fate of an activated B cell following mitogen stimulation can be dictated by the strength or duration of the signal, the expression of downstream signaling components necessary to promote proliferation, and the cell intrinsic sensors and regulators of the proliferative program. Previously we have identified the DNA damage response (DDR) signaling pathway as a cell intrinsic sensor that is activated upon latent infection of primary human B cells by Epstein-Barr virus (EBV). Here we have assessed the role of the DDR as a limiting factor in the proliferative response to non-viral B-cell mitogens. We report that TLR9 activation through CpG-rich oligonucleotides induced B-cell hyper-proliferation and an ATM/Chk2 downstream signaling pathway. However, B-cell activation through the CD40 pathway coupled with interleukin-4 (IL-4) promoted proliferation less robustly and only a modest DDR. These two mitogens, but not EBV, modestly induced intrinsic apoptosis that was independent from the DDR. However, all three mitogens triggered a DDR-dependent G1/S phase cell cycle arrest preventing B-cell proliferation. The extent of G1/S arrest, as evidenced by release through Chk2 inhibition, correlated with B-cell proliferation rates. These findings have implications for the regulation of extra-follicular B-cell activation as it may pertain to the development of auto-immune diseases or lymphoma.

Citing Articles

Insights into the Absence of Lymphoma Despite Fulminant Epstein-Barr Virus Infection in Patients with XIAP Deficiency.

Sun Y, Chou J, Dong K, Gygi S, Gewurz B bioRxiv. 2025; .

PMID: 39868266 PMC: 11761029. DOI: 10.1101/2025.01.17.633616.


Epstein-Barr virus reactivation induces divergent abortive, reprogrammed, and host shutoff states by lytic progression.

SoRelle E, Haynes L, Willard K, Chang B, Chng J, Christofk H PLoS Pathog. 2024; 20(10):e1012341.

PMID: 39446925 PMC: 11563402. DOI: 10.1371/journal.ppat.1012341.


Epstein-Barr virus reactivation induces divergent abortive, reprogrammed, and host shutoff states by lytic progression.

SoRelle E, Haynes L, Willard K, Chang B, Chng J, Christofk H bioRxiv. 2024; .

PMID: 38915538 PMC: 11195279. DOI: 10.1101/2024.06.14.598975.


The Research Progress on Immortalization of Human B Cells.

Xu H, Xiang X, Ding W, Dong W, Hu Y Microorganisms. 2023; 11(12).

PMID: 38138080 PMC: 10746006. DOI: 10.3390/microorganisms11122936.


Contribution of viral and bacterial infections to senescence and immunosenescence.

Reyes A, Ortiz G, Duarte L, Fernandez C, Hernandez-Armengol R, Palacios P Front Cell Infect Microbiol. 2023; 13:1229098.

PMID: 37753486 PMC: 10518457. DOI: 10.3389/fcimb.2023.1229098.


References
1.
Tort F, Hernandez S, Bea S, Martinez A, Esteller M, Herman J . CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood. 2002; 100(13):4602-8. DOI: 10.1182/blood-2002-04-1078. View

2.
Tsujimoto Y, Cossman J, Jaffe E, Croce C . Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985; 228(4706):1440-3. DOI: 10.1126/science.3874430. View

3.
Di Micco R, Sulli G, Dobreva M, Liontos M, Botrugno O, Gargiulo G . Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol. 2011; 13(3):292-302. PMC: 3918344. DOI: 10.1038/ncb2170. View

4.
Toellner K, Taylor D, Sze D, MacLennan I . Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. J Exp Med. 1996; 183(5):2303-12. PMC: 2192570. DOI: 10.1084/jem.183.5.2303. View

5.
Bartek J, Bartkova J, Lukas J . DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. 2007; 26(56):7773-9. DOI: 10.1038/sj.onc.1210881. View